Asgard Therapeutics Appoints Wolfram Brugger as Chief Medical Officer

Published: 2026-04-14 11:38:01 ET AUTL

Published on 04/14/2026 at 11:38 am EDT

Asgard Therapeutics announced the appointment of Prof Dr Wolfram Brugger as Chief Medical Officer, effective April 14, 2026. Prof Dr Brugger has been involved in more than 130 Phase I-III clinical oncology trials with numerous modalities across a wide variety of cancer types, including solid tumors. Wolfram joins Asgard from NASDAQ-listed Autolus Therapeutics where he led the global clinical development program of AUTO1 (AUCATZYL® /obe-cel), an autologous CD19 CAR T therapy, in hematological and autoimmune indications.

AUTO1 received FDA approval in 2024 for relapsed /refractory B-cell acute lymphoblastic leukemia (B-ALL) and conditional approval was granted by the EMA and MHRA in 2025. Prior to this he was at MorphoSys where he headed the global clinical development program for the monoclonal antibody tafasitamab across various blood cancer indications. Tafasitamab (in combination with lenalidomide) was granted accelerated approval by the FDA in relapsed/refractory DLBCL in 2020 and conditional approval by the EMA in the same indication in 2021.

At AstraZeneca, he was global medical lead for Phase I /early Phase II trials for several oncology assets in numerous cancer types, including testing them in combination with checkpoint inhibitors. Prior to moving into drug development, he was Chief & Medical Director in the Department of Hematology, Oncology, Immunology & Infectious Diseases at a Teaching Hospital of Freiburg University in Germany. He holds an MD and PhD from Albert-Ludwigs University Freiburg and Eberhard-Karls University Tübingen, Germany, with a specialist registration in Internal Medicine, Medical Oncology and Hematology.